Rutaecarpine derivative Cpd-6c alleviates acute kidney injury by targeting PDE4B, a key enzyme mediating inflammation in cisplatin nephropathy
Authors:
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 180, 114132
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 58 references indexed in Scilit:
- Proinflammatory cytokine regulation of cyclic AMP‐phosphodiesterase 4 signaling in microglia in vitro and following CNS injuryGlia, 2012
- Pathophysiology of ischemic acute kidney injuryNature Reviews Nephrology, 2011
- Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia rutaecarpaMolecules, 2009
- INVOLVEMENT OF PROLYLCARBOXYPEPTIDASE IN THE EFFECT OF RUTAECARPINE ON THE REGRESSION OF MESENTERIC ARTERY HYPERTROPHY IN RENOVASCULAR HYPERTENSIVE RATSClinical and Experimental Pharmacology and Physiology, 2009
- NADPH Oxidases, Reactive Oxygen Species, and HypertensionDiabetes Care, 2008
- Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agentsPharmacology & Therapeutics, 2006
- Alteration of the pharmacokinetics of theophylline by rutaecarpine, an alkaloid of the medicinal herb Evodia rutaecarpa, in ratsJournal of Pharmacy and Pharmacology, 2005
- Stimulation of calcitonin gene-related peptide synthesis and releaseJournal Of Hypertension, 2004
- cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injuryNature Medicine, 2004
- Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidneyKidney International, 1999